<DOC>
	<DOCNO>NCT00074152</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether chemotherapy effective treat woman undergone surgery radiation therapy relapse breast cancer . PURPOSE : Randomized phase III trial determine effectiveness adjuvant chemotherapy treat woman undergone resection local and/or regional relapse breast cancer .</brief_summary>
	<brief_title>Adjuvant Chemotherapy Treating Women Who Have Undergone Resection Relapsed Breast Cancer ; Chemotherapy Adjuvant LOcally Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy adjuvant chemotherapy , term disease-free survival , woman radically resect loco-regional relapsed breast cancer . Secondary - Determine systemic disease-free overall survival patient treat regimen . - Determine sit recurrence , incidence second ( non-breast ) malignancy , cause death without relapse breast cancer patient treat regimen . - Determine quality life patient treat regimen ( QOL portion close 11/13/08 ) . OUTLINE : This randomize , multicenter study . Patients stratify accord prior chemotherapy ( yes v ) , estrogen receptor ( ER ) positive and/or progesterone receptor ( PR ) positive ( yes v ) , location recurrence ( breast v mastectomy scar/chest wall v regional lymph node ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive radiotherapy* within 6 month surgery . - Arm II : Within 10 week surgery , patient receive least 3 course adjuvant chemotherapy regimen determine investigator . Patients also receive radiotherapy* within 6 month surgery completion chemotherapy OR integrate chemotherapy . NOTE : *Patients clear margin ( R0 ) receive prior adjuvant radiotherapy require receive radiotherapy Patients ER and/or PR positive tumor also receive standard hormonal therapy . Quality life assess baseline 9 12 month ( QOL portion close 11/13/08 ) . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 265 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast cancer First local and/or regional ( i.e. , ipsilateral axillary internal mammary lymph node region ) recurrence primary treatment mastectomy lumpectomy/quadrantectomy clear surgical margin Local failure define tumor recurrence soft tissue ipsilateral conserve breast chest wall , mastectomy scar , and/or skin Regional failure define tumor recurrence ipsilateral axillary lymph node , extranodal soft tissue ipsilateral axilla , and/or ipsilateral internal mammary . Regional failure include supraclavicular lymph node tumor opposite breast No prior recurrence site , include local Surgical resection recurrence meeting 1 follow criterion : Uninvolved ( `` clear '' ) margin plan radiotherapy least 40 Gy patient prior adjuvant radiotherapy Mastectomy recurrence uninvolved ( `` clear '' ) margin lumpectomy/quadrantectomy alone primary Adjuvant trastuzumab ( HerceptinÂ® ) therapy HER2 direct therapy allow patient HER2 positive tumor must declare prior randomization No evidence distant metastasis , include ipsilateral supraclavicular lymph node , xray CT scan chest , ultrasound CT scan abdomen pelvis , bone scintigraphy alkaline phosphatase &gt; 2 time normal medically indicate ( e.g. , bone pain ) No macroscopically incomplete surgery No bilateral malignancy except carcinoma situ No suspicious mass opposite breast unless mass proven biopsy benign No skeletal pain unknown cause No hot spot bone scan metastasis rule xray , MRI , and/or CT scan Hormone receptor status : Determined recurrent tumor immunohistochemistry and/or ligandbinding assay Estrogen receptor positive negative Progesterone receptor positive negative PATIENT CHARACTERISTICS : Age Minimum 18 year Sex Female Menopausal status Not specify Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic No elevate alkaline phosphatase Renal Not specify Other Fertile patient must use effective nonhormonal contraception Medically suitable chemotherapy 36 month duration No primary malignant tumor except adequately treat carcinoma situ cervix nonmelanoma skin cancer No nonmalignant systemic disease would preclude study treatment prolong followup No psychiatric addictive disorder would preclude give informed consent No history noncompliance medical regimen potential unreliable PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy See Disease Characteristics Surgery See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>